Business Context and Reporting Period
This Form 8-K is filed by Aerpio Pharmaceuticals, Inc. (not Whitehawk Therapeutics, Inc.) on August 8, 2019. The filing serves to announce the company's financial results for the quarter ended June 30, 2019. The registrant is an emerging growth company incorporated in Delaware with its principal executive offices in Cincinnati, Ohio.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. The document acts as a notification that these results have been announced and directs readers to Exhibit 99.1 (the press release) for the detailed financial data.
Material Changes
No material changes or comparative financial data are disclosed within the body of this Form 8-K. The filing explicitly states that the information is furnished and not "filed" for purposes of Section 18 of the Exchange Act, deferring all operational details to the attached press release.
Guidance, Outlook, and Risks
The text contains no management commentary, forward-looking guidance, risk factors, or discussion of contingencies. It strictly references the existence of the press release issued on the same date for further information.
Investor Verification Checklist
- Verify the discrepancy between the requested company name (Whitehawk Therapeutics) and the filing registrant (Aerpio Pharmaceuticals).
- Review Exhibit 99.1 (the press release) to obtain actual revenue, net loss, and cash position figures for the quarter ended June 30, 2019.
- Confirm the company's status as an emerging growth company and its election regarding extended transition periods for accounting standards.
- Check the Nasdaq Capital Market listing status under the symbol ARPO.